Safety and Efficacy of Microneedling as an Adjunctive Therapy to Topical Adapalene 0.1% in Treating Mild-to-Moderate Acne Vulgaris: A Split-Face Comparative Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202607470891232

Enrollment

Registered

2026-07-07

Start date

2024-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Microneedling

adapalene

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: males and females aged 14–40 years with mild to moderate acne vulgaris characterized by open or closed comedones, inflammatory papules or pustules

Exclusion criteria

Exclusion criteria: Pregnancy or lactation nodulocystic acne unilateral facial acne topical or systemic acne therapy within 4 weeks prior cosmetic procedures within 1–2 years active local infection or inflammatory dermatosis melanoma or premalignant lesions systemic diseases (hypertension, diabetes, bleeding disorders) anticoagulant therapy history of keloid or hypertrophic scarring

Design outcomes

Primary

Measure	Time frame
Acne severity assessed by Acne Severity Score (ASS) grading and lesion counts (comedones, papules, and pustules) on each side of the face	—

Secondary

Measure	Time frame
Investigator's Global Assessment (IGA) score; patient satisfaction (4-point scale); safety and adverse events (local irritation, dryness, edema, bruising)	—

Countries

Egypt

Contacts

Public ContactNouran Jad Elhak

Resident Physician Helwan University

nouranjad35@gmail.com+201021786018

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 10, 2026